Physician profile
William Williams
NPI 1487875522
$9,262.96
in general payments reported to CMS, 2019-2025
37 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $1,350 · 2021: $1,436 · 2022: $1,175 · 2023: $1,259 · 2024: $1,496 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Education: $23.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.93 |
| Education | $23.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,601.95 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $932.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $894.98 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $615.97 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $567.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.11 | 2019-2025 | Jardiance |
| Pfizer INC. | $350.75 | 2019-2025 | |
| Allergan, INC. | $281.49 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.90 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $176.15 | 2019-2023 | |
| Lilly USA, LLC | $147.57 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $142.97 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.86 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $109.44 | 2019-2023 | Xarelto |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $106.71 | 2020-2022 | |
| Almatica Pharma LLC | $97.80 | 2023-2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $91.15 | 2019 | |
| Mylan Specialty L.P. | $79.64 | 2019-2023 | Yupelri |
| Amarin Pharma, INC. | $63.62 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $60.73 | 2024-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $56.87 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.01 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.33 | 2022 | |
| Genentech USA, INC. | $25.66 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.17 | 2019 | |
| Astellas Pharma US INC | $20.41 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.56 | 2024 | Voquezna |
| Lundbeck LLC | $18.78 | 2025 | Rexulti |
| Boston Scientific Corporation | $17.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2019 | |
| Exact Sciences Corporation | $15.65 | 2025 | Cologuard Collection Kit |
| Phadia US INC. | $15.37 | 2021 | |
| Sumitomo Pharma America, INC. | $15.30 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $14.26 | 2022 | |
| Gilead Sciences, INC. | $13.07 | 2021 | |
| Lupin INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.